Generation of integration-free human induced pluripotent stem cell line MUi040-A derived from CD34 + hematopoietic stem cells of a patient with constitutional pericentric inversion of chromosome 9
- Stem Cell Res. 2025 Dec:89:103866. doi: 10.1016/j.scr.2025.103866.
- 1. Excellent Center for Drug Discovery, Faculty of Science, Mahidol University, Bangkok 10400 Thailand.
- 2. Department of Anatomy, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
- 3. Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
- 4. Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand.
- 5. Department of Medical Genetics, College of Health Sciences, VinUniversity, Hanoi 10000, Vietnam; Center for Global Health, Perelman School of Medicine, University of Pennsylvania, PA 19104, USA; Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
- 6. Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bang Pla, Bang Phli, Samut Prakan 10540, Thailand.
- 7. Excellent Center for Drug Discovery, Faculty of Science, Mahidol University, Bangkok 10400 Thailand; Department of Biotechnology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
- 8. Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. Electronic address: [email protected].
The MUi040-A human induced pluripotent stem cell (hiPSC) line was established from CD34 + hematopoietic stem cells of a male patient with senile amyloidosis. Patient carries a unique chromosome inversion at bands 9p12 and 9q13, which is one of the most common variants of the normal karyotype of chromosome 9 (inv[9]). This hiPSC line maintains an identical karyotype to that of the parental cells. MUi040-A expressed pluripotency markers and demonstrated the capacity to differentiate into all three germ layers. This cell line offers a valuable in vitro for studying the pathophysiology of senile systemic amyloidosis and for evaluating potential therapeutic approaches.